THE SCIENCE
The Science Behind
Our Antibody Platform
Our research focuses on developing highly selective
monoclonal antibodies targeting disease-relevant alpha-synuclein
structures with applications in diagnostics, brain imaging,
and future therapeutics.
early-stage
Precision Diagnostics
The ability to identify neurodegenerative disease before extensive neuronal damage has occurred remains one of the most important unmet needs in modern medicine. Current diagnostic approaches often rely on clinical symptoms that appear relatively late in the disease process, limiting opportunities for early intervention and personalized patient management.
As illustrated in Figure 1, Core-Oli-T AB’s diagnostic approach combines blood plasma analysis with fibril-specific monoclonal antibodies designed to detect disease-associated alpha-synuclein aggregates.
At Core-Oli-T AB, we believe that disease-associated alpha-synuclein aggregates contain valuable biological information that can be used to improve diagnostic precision. Emerging research suggests that different aggregate conformations may be associated with distinct disease phenotypes and rates of progression.
Our antibody platform is designed to selectively recognize pathological protein structures that are not detected by conventional approaches. By focusing on disease-relevant molecular signatures rather than total protein abundance, we aim to provide a more precise view of the underlying pathology.
Ultimately, early and accurate identification of pathological alpha-synuclein species could support improved patient stratification, facilitate clinical decision-making, and help advance the development of precision medicine approaches for Parkinson’s disease and related synucleinopathies.
Figure 1. Early-stage precision diagnostics using fibril-specific monoclonal antibodies.
Core-Oli-T develops fibril-specific monoclonal antibodies that selectively recognize disease-associated alpha-synuclein aggregates in blood plasma. (1) A blood sample is collected from the patient and processed to obtain plasma. (2) Centrifugation separates plasma from blood cells and other cellular components. (3) Plasma samples are analyzed using fibril-specific monoclonal antibodies that selectively bind distinct alpha-synuclein fibril conformations associated with neurodegenerative disease. (4) The resulting binding profiles enable the detection and characterization of disease-associated alpha-synuclein species, supporting early diagnosis, patient stratification, and differentiation between related synucleinopathies such as Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy.
Late-stage
Brain Imaging
Understanding the distribution and progression of pathological alpha-synuclein aggregates within the brain remains a major challenge in Parkinson’s disease research. While clinical symptoms provide important information about disease severity, they offer only limited insight into the underlying molecular pathology driving neurodegeneration.
As illustrated in Figure 2, Core-Oli-T is developing fibril-specific monoclonal antibodies that may enable the visualization of disease-associated alpha-synuclein aggregates through advanced molecular imaging approaches. By selectively targeting pathological fibril structures, these antibodies have the potential to reveal where and to what extent pathology is present within the brain.
The ability to visualize pathological protein aggregates in vivo could provide valuable information for disease characterization, patient stratification, and longitudinal monitoring. Such approaches may also help improve our understanding of how alpha-synuclein pathology spreads through the nervous system over time.
Ultimately, molecular imaging based on fibril-specific antibodies could complement traditional clinical assessments by providing a direct view of disease-associated pathology, supporting more informed decision-making in both research and future clinical applications.
Figure 2. Late-stage brain imaging using fibril-specific monoclonal antibodies.
Core-Oli-T develops fibril-specific monoclonal antibodies that selectively recognize disease-associated alpha-synuclein aggregates in the brain. (1) Pathological alpha-synuclein fibrils accumulate in affected brain regions during disease progression. (2) Fibril-specific monoclonal antibodies selectively bind these disease-associated protein aggregates while sparing physiological protein forms. (3) Antibody binding enables visualization of pathological alpha-synuclein deposits through advanced molecular imaging techniques. The resulting brain images reveal the distribution and burden of disease-associated pathology, supporting disease characterization, patient stratification, and monitoring of disease progression.
early-stage
Therapeutic Intervention
One of the greatest challenges in Parkinson’s disease and related synucleinopathies is that pathological alpha-synuclein aggregates may begin to spread through the nervous system years before the onset of severe clinical symptoms. By the time many patients receive a diagnosis, substantial neuronal damage may already have occurred, limiting the effectiveness of therapeutic intervention.
As illustrated in Figure 3, Core-Oli-T is developing fibril-specific monoclonal antibodies designed to selectively target disease-associated alpha-synuclein aggregates during the early stages of disease progression. By recognizing pathogenic fibril structures while sparing physiological protein forms, these antibodies aim to interfere with the mechanisms that drive the propagation of pathology between neurons.
Targeting pathological alpha-synuclein at an early stage may provide an opportunity to slow disease progression before extensive neurodegeneration has occurred. Such an approach could help preserve neuronal function and support long-term disease management.
Ultimately, fibril-specific antibody therapeutics represent a promising precision medicine strategy that seeks to address the underlying pathology of Parkinson’s disease rather than simply managing clinical symptoms.
Figure 3. Early therapeutic intervention using fibril-specific monoclonal antibodies.
Core-Oli-T develops fibril-specific monoclonal antibodies designed to selectively target disease-associated alpha-synuclein aggregates during the early stages of disease progression. By recognizing pathogenic fibril structures while sparing physiological protein forms, these antibody candidates aim to reduce the propagation of alpha-synuclein pathology, preserve neuronal function, and support improved long-term clinical outcomes.
SCIENTIFIC FOUNDATION
Selected Publications
The scientific foundation of Core-Oli-T is built upon pioneering research into alpha-synuclein aggregation, oligomer formation, and fibril polymorphism. The studies below established key insights that later enabled the development of our fibril-specific antibody platform.
AMYLOID FIBRIL
FORMATION
Scientific Reports, 2019
This study investigated amyloid fibrils formed by the NAC region of alpha-synuclein and revealed structural features linked to pathogenic protein aggregation.
SOLUBLE OLIGOMER
FORMATION
International Journal of Molecular Science, 2020
This study demonstrated the formation of soluble β-sheet-rich oligomers from the NAC region of alpha-synuclein. The findings improved our understanding of early pathogenic protein aggregation.
FIBRIL STRUCTURAL POLYMORPHISM
International Journal of Molecular Science, 2021
This study generated structurally distinct alpha-synuclein-like fibrils from synthetic NAC 71–82 peptides. The findings provided insights into disease-associated fibril polymorphism.